Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen ...Middle East

PR Newswire - News
Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen
STOCKHOLM, Oct. 26, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces data from the phase 3 LIGHTHOUSE study that further confirms the...

Hence then, the article about oncopeptides phase 3 lighthouse study further confirms clinical benefit of melflufen was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen )

Apple Storegoogle play

Last updated :

Also on site :